Send us your contact and we’ll be back to you as soon as posible
MOLEFY’s goals include the production of AP-2 to semi-industrial level and efficient oral administration of the drug.
MOLEFY’ s approach is supported by encouraging data from animal and patient-based cellular models. AP-2 has shown effectiveness and promising pharmacological safety profile in rodent and non-rodent animal models.
MOLEFY’ s approach is supported by encouraging data from animal and patient-based cellular models. AP-2 has shown effectiveness and promising pharmacological safety profile in rodent and non-rodent animal models.
MOLEFY is eager to expand its reach to establish strategic partnerships and connections with leading research institutions, pharmaceutical companies, and regulatory bodies. By forging alliances with key stakeholders we aim to accelerate the develpoment and commercialization of our molecule designed to target the underlying mechanisms of ALS.We have assembled a talented team of scientists and clinicians dedicated to advancing ALS research and developing effective treatments. With a simple funding and robust intelectual property protection, we are well-positioned to scale up our operations and bring our molecule to market.
We are commited to providing a pathway towards potentially reversing Amyotrophic Lateral Sclerosis (ALS), a debilitating neurodegenerative condition marked by progressive muscle control loss with no effective treatment. Efforts to advance research into effective treatments are essential to mitigate the impact of this devastating disease not only on patients but also in the national health systems. The situation is set to worsen dramatically in the next 15 years, with a significant rise in the number of cases.
Efforts to advance research into effective tratments are essential to mitigate the impact of this devastating disease not only on patients but also in the national health system:
Neurodegenerative Desease Costs Exceed 650 billion a year in medical expenses and economic losses
To tackle the urgent need for better treatments, MOLEFY is working on a small molecule called AP-2. This compound has shown promise in early testing by helping regulate a kinase that can restore balance to TDP-43 in ALS patients. This protein accumulates abnormaly in motor neurons, driving their degenaration
and eventual demise. Outstanding recent preclinical trials in animal models have
shown that blocking TDP-43’s abnormal behaviour not only relieves ALS symptons but also reverses cellular homeostasis.
To tackle the urgent need for better treatments, MOLEFY is working on a small
molecule called AP-2. This compound has shown promise in early testing by
helping regulate a kinase that can restore balance to TDP-43 in ALS patients. This protein accumulates abnormaly in motor neurons, driving their degenaration
and eventual demise. Outstanding recent preclinical trials in animal models have
shown that blocking TDP-43’s abnormal behaviour not only relieves ALS
symptons but also reverses disease progression.
To tackle the urgent need for better treatments, MOLEFY is working on a small molecule called AP-2. This compound has shown potential in early testing by helping regulate a kinase that can restore balance to TDP-43 in ALS patients. This protein accumulates abnormaly in motor neurons, driving their degenaration and eventual death. Outstanding recent preclinical trials in animal models have shown that blocking TDP-43’s abnormal behaviour not only relieves ALS symptons but also reverses disease progression.
No Data Found
No Data Found
No Data Found
MOLEFY is supported by leading technology and science companies and institutions:.
Supported by:
In collaboration with:
Efforts to advance research into effective treatments are essential to mitigate the impact of this devastating disease, not only on patients and their families but also on society and healthcare systems. The situation is set to worsen dramatically in the next 15 years, with a significant rise in the number of cases.
Efforts to advance research into effective treatments are essential to mitigate the impact of this devastating disease not only on patients but also in the national health system.
Molecules
AP-2
Disease
ALS
Target
CK1δ
AP-2
AP-2
ALS
ALS
CK1δ
CK1δ
Efforts to advance research into effective treatments are essential to mitigate the impact of this devastating disease not only on patients but also in the national health system.
Molecules
AP-3
Disease
FTD/AD
Target
TTBK1
Our interdisciplinary team brings toguether extensive expertise in technology transfer and innovation
READ ALL
Moley Pharma, a spin-off of the CSIC in collaboration with ARQUIMEA dedicated to finding a cure for amyotrophic lateral sclerosis (ALS) through the AP-2 molecule, has won first prize in the eighth edition of the Investment Forum of the Science and Technology Park of Tenerife. The event, held as part of the second edition of […]
Amyotrophic Lateral Sclerosis (ALS), is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over time, it leads to the weakening of muscles, loss of mobility, and eventually difficulty speaking, swallowing, and breathing. While the exact cause is unknown, it is characterized by the gradual deterioration of motor neurons, which are responsible for controlling voluntary muscles. ALS has no cure. It is often associated with famous figures such as physicist Stephen Hawking.
The socioeconomic impact of Amyotrophic Lateral Sclerosis (ALS) is significant due to the high costs of medical care and the loss of productivity. The average annual cost for an ALS patient can range from $30,000 to over $200,000, depending on the severity of the disease and care required, including hospital visits, assistive devices, and home care. Patients typically lose their ability to work within two years of diagnosis, leading to household income losses, while family members who become caregivers also face financial strain. In the U.S., ALS patients often rely on disability benefits and Medicare, adding pressure to public welfare systems. The emotional toll on families can further lead to increased mental health care costs, adding to the overall burden. Globally, the cost of ALS is estimated to reach billions annually due to these factors.
Molefy’s current goal is to achieve funding for the first phase of the clinical trial, for which 3 million euros are required. For more information, please contact hello@molefy.com
Send us your contact and we’ll be back to you as soon as posible
Send us your contact and we’ll be back to you as soon as posible